NCT05702463View on ClinicalTrials.gov

Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 13, 2023

Primary Completion Date

June 1, 2027

Study Completion Date

July 1, 2027

Conditions
Platelet AggregationType 2 DiabetesAspirinDiabetes Mellitus, Type 2Platelet Aggregation Inhibitors
Interventions
DRUG

Aspirin 81Mg Ec Tab twice daily for 7 days

Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.

DRUG

Aspirin 40Mg Chew Tab twice daily for 7 days

Participants with incomplete platelet aggregation will be instructed to take chewable ASA 40 mg twice daily for 7 days.

DRUG

Aspirin 162 mg EC Tab once daily for 7 days

Participants with incomplete platelet aggregation will be instructed to take EC ASA 162 mg once daily for 7 days.

Trial Locations (1)

H1T 1C8

RECRUITING

Montreal Heart Institute, Montreal

All Listed Sponsors
collaborator

Heart and Stroke Foundation of Canada

OTHER

lead

Montreal Heart Institute

OTHER